Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target

S Yang, X Li, F Yang, R Zhao, X Pan, J Liang… - Frontiers in …, 2019‏ - frontiersin.org
Cardiovascular disease (CVD) is the leading cause of death worldwide, especially in
developed countries, and atherosclerosis (AS) is the common pathological basis of many …

Immunothrombosis and thromboinflammation in host defense and disease

K Martinod, C Deppermann - Platelets, 2021‏ - Taylor & Francis
Platelets are increasingly being recognized for playing roles beyond thrombosis and
hemostasis. Today we know that they mediate inflammation by direct interactions with innate …

Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk

W Zhu, JC Gregory, E Org, JA Buffa, N Gupta, Z Wang… - Cell, 2016‏ - cell.com
Normal platelet function is critical to blood hemostasis and maintenance of a closed
circulatory system. Heightened platelet reactivity, however, is associated with …

Inhalable stem cell exosomes promote heart repair after myocardial infarction

J Li, S Sun, D Zhu, X Mei, Y Lyu, K Huang, Y Li, S Liu… - Circulation, 2024‏ - ahajournals.org
BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However,
intrinsic challenges such as short half-life and lack of clear targets hinder the clinical …

[HTML][HTML] Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol

I Erlund, R Koli, G Alfthan, J Marniemi, P Puukka… - The American journal of …, 2008‏ - Elsevier
Background: Berries are a particularly rich source of polyphenols. They also contain other
bioactive substances, such as vitamin C. Previous studies indicated that the consumption of …

von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes

AO Spiel, JC Gilbert, B Jilma - Circulation, 2008‏ - Am Heart Assoc
von Willebrand factor (VWF) plays a pivotal role in platelet adhesion and aggregation at
sites of high shear rates (eg, in coronary arteries that have stenotic or ruptured …

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized …

A Kastrati, J Mehilli, FJ Neumann, F Dotzer, J Ten Berg… - Jama, 2006‏ - jamanetwork.com
ContextNo specifically designed studies have addressed the role of the glycoprotein IIb/IIIa
inhibitor abciximab in patients with non–ST-segment elevation acute coronary syndromes …

Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with st-segment–elevation myocardial infarction: primary results of the FABOLUS …

G Gargiulo, G Esposito, M Avvedimento, M Nagler… - Circulation, 2020‏ - Am Heart Assoc
Background: Standard administration of newer oral P2Y12 inhibitors, including prasugrel or
ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with …

Platelet function testing in cardiovascular diseases

AD Michelson - Circulation, 2004‏ - Am Heart Assoc
e489 20% of patients with an arterial thrombotic event who are treated with aspirin have a
recurrent arterial thrombotic event during long-term follow-up. 14 The failure of aspirin to …

Clinical utility of the PFA-100

EJ Favaloro - Seminars in thrombosis and hemostasis, 2008‏ - thieme-connect.com
The PFA-100 (platelet function analyzer) is a relatively new tool for the investigation of
primary hemostasis. This article reviews the history of the PFA-100 and details its clinical …